• Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
Friday, February 3, 2023
Cameron County News Online
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Popular
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Popular
No Result
View All Result
No Result
View All Result
Home News

Alzheimer’s Drugmakers Seek Accelerated FDA Review Despite U.S. Coverage Decision – Reuters.com

by NewsReporter
April 9, 2022
in News
Reading Time: 3 mins read
alzheimer’s-drugmakers-seek-accelerated-fda-review-despite-us-coverage-decision-–-reuters.com
Share on FacebookShare on Twitter

The logo of Eisai Co Ltd is displayed at the company headquarters in Tokyo, Japan, March 8, 2018. REUTERS/Issei Kato

Register now for FREE unlimited access to Reuters.com

April 8 (Reuters) – Eisai Co Ltd (4523.T) and Eli Lilly and Co (LLY.N) on Friday said they still plan to seek accelerated U.S. approval for experimental Alzheimer’s drugs even after the Medicare health plan decided to severely limit coverage of medicines approved in that manner.

On Thursday, after a months-long review and a pressure campaign from patient advocacy groups, the Centers for Medicare and Medicaid Services (CMS) said it would only pay for Biogen Inc’s (BIIB.O) Aduhelm, and other drugs that work in a similar fashion, for patients enrolled in valid clinical studies, unless the treatments demonstrate clear evidence of patient benefit.

Medicare covers nearly 64 million Americans age 65 and older, so the coverage decision could affect 85% of people who might otherwise use the medications for the age-related condition.

Register now for FREE unlimited access to Reuters.com

Eisai’s lecanemab and Lilly’s donanemab, like Aduhelm, are monoclonal antibodies designed to remove beta-amyloid, a type of protein fragment that accumulates in the brains of Alzheimer’s patients. The two drugmakers said they expect upcoming Phase III trial results to eventually validate earlier-stage data under review by the U.S. Food and Drug Administration.

A fourth plaque-targeting antibody, gantenerumab, is in late-stage development at Roche Holding AG (ROG.S), which is not seeking an accelerated FDA review.

The FDA in June authorized Biogen’s Aduhelm – the first drug in this class and first U.S. approved Alzheimer’s treatment in 20 years – under the agency’s accelerated pathway based on the drug’s plaque-clearing ability, rather than proof it slows cognitive decline in Alzheimer’s patients.

Medicare, however, has decided to allow standard reimbursement only for Alzheimer’s drugs approved under the traditional FDA process based on “a direct measure of clinical benefit.”

Eisai, which is partnered with Biogen, said it aims to complete a rolling FDA application for lecanemab, under the accelerated pathway, by mid-year. The Japanese drugmaker said it also expects results from its 1,800-patient, Phase III trial this fall.

If those results are positive, Eisai said it believes the large study could meet the “high level of evidence” criteria set by Medicare in its coverage decision.

The study is designed to show that lecanemab can slow by at least 25% the rate of cognitive and functional decline.

“It is a disease-modifying drug,” Ivan Cheung, Eisai’s U.S. chairman, said in a recent interview with Reuters. “You expect to see separation between the treated and untreated groups that improves over time.”

Roche also expects to report Phase III trial results for gantenerumab later this year.

Lilly, in a statement, said it intends to complete its current, rolling application for accelerated FDA approval of donanemab this year. It does not expect to have results from a Phase III trial of the drug until mid-2023.

The Indianapolis-based company said it believes Medicare coverage restrictions are “unnecessary, restrictive and inappropriate” for FDA-approved drugs.

The idea that removing amyloid plaques is reasonably likely to slow cognitive and functional decline in people living with early Alzheimer’s is known as the “amyloid hypothesis,” a theory that has led to long history of drugs that tried and failed to clear the plaques or help patients.

Greg Rippon, neuroscience and Alzheimer’s Disease medical lead at Roche’s Genentech unit, explained in a recent interview that the theory is supported by analysis of inherited forms of Alzheimer’s, which are all caused by mutations in amyloid processing.

He said more recent studies have shown that the build-up of amyloid is a precursor to other brain dysfunction that speeds neurodegeneration for patients with Alzheimer’s.

“Obviously, it comes down to clinical data and demonstrating that clinical benefit and that’s where a lot of skepticism is centered,” Rippon said.

(This story was refiled to correct spelling of ‘plaques’ in paragraph 15)

Register now for FREE unlimited access to Reuters.com

Reporting By Deena Beasley Editing by Bill Berkrot

Our Standards: The Thomson Reuters Trust Principles.

Related Posts

troup-county-sheriff’s-office-arrest-release-reports-for-period-ending-april-14-–-lagrange-daily-news-|-lagrange-daily-news-–-lagrange-daily-news

Troup County Sheriff’s Office Arrest Release Reports For Period Ending April 14 – LaGrange Daily News | LaGrange Daily News – LaGrange Daily News

by NewsReporter
April 14, 2022
0

Amari Keshad Towns, 21, 115 Haley Way, LaGrange, GA, theft – other (felony Michael Randall Reynolds, 27, 1114 Alverson Road, LaGrange, GA, VGCSA-amphetamine-possession Maria Montana Phillips, 41, 421 South Lee Street D-22, LaGrange, GA, failure to appear (state) Crystal Nichol Gates, 38, no known address, remove/affix plate with intent to...

musk-says-us.-sec-‘bastards’-forced-settlement-over-tesla-tweets-–-reuters

Musk Says U.S. SEC ‘bastards’ Forced Settlement Over Tesla Tweets – Reuters

by NewsReporter
April 14, 2022
0

Tesla CEO Elon Musk leaves Manhattan federal court after a hearing on his fraud settlement with the Securities and Exchange Commission (SEC) in New York City, U.S. April 4, 2019. REUTERS/Brendan McDermidRegister now for FREE unlimited access to Reuters.comApril 14 (Reuters) - Tesla Inc (TSLA.O) CEO Elon Musk on Thursday...

democrats-are-in-danger-of-losing-three-congressional-strongholds-in-south-texas-–-ksat-san-antonio

Democrats Are In Danger Of Losing Three Congressional Strongholds In South Texas – KSAT San Antonio

by NewsReporter
April 14, 2022
0

Sign up for The Brief, our daily newsletter that keeps readers up to speed on the most essential Texas news.WASHINGTON — Fending off the Republican advance in South Texas this fall was already going to be a taller-than-usual order for Democrats. But few Democrats anticipated it would be this hard.Thanks...

column:-crop-watch:-cold-spring-weather-prevents-early-us.-planting-–-reuters

Column: Crop Watch: Cold Spring Weather Prevents Early U.S. Planting – Reuters

by NewsReporter
April 14, 2022
0

Acres of soybeans seen at the Pioneer-DuPont Seed facility in Addieville, Illinois U.S., September 19, 2018. Picture taken September 19, 2018. REUTERS/Lawrence BryantRegister now for FREE unlimited access to Reuters.comNAPERVILLE, Ill., April 13 (Reuters) - It is too early yet for U.S. corn and soybean planting to be in full...

Cameron County News Online

© 2021 Salt Lake City News Now

Navigate Site

  • Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer

Follow Us

No Result
View All Result
  • Home
  • DMCA Policy
  • Medical Disclaimer
  • Privacy Policy
  • Disclosure
  • CCPA
  • Terms of Use

© 2021 Salt Lake City News Now

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT